What Is Soliqua?

1. What Is Soliqua?

Soliqua 100/33 is a Sanofi brand name for a prescription injection that combines insulin glargine and lixisenatide. The current DailyMed Soliqua label describes it as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

One pen, two active ingredients.

Insulin glargine is a long-acting human insulin analog. Lixisenatide is a glucagon-like peptide-1, or GLP-1, receptor agonist. The label calls Soliqua a combination of insulin glargine and lixisenatide, not a standalone insulin and not a standalone GLP-1 product.

Breaking down the naming stack makes it clear:

That last point matters more than it looks. “Soliqua” is too specific to mean “any insulin,” “any GLP-1,” or “any daily diabetes injection.” It is its own product label.

2. What Does Soliqua 100/33 Mean?

The “100/33” in the name is concentration language. DailyMed lists Soliqua 100/33 as 100 units insulin glargine and 33 mcg lixisenatide per mL in a 3 mL prefilled, disposable, single-patient-use SoloStar pen.

So the numbers are not a personal dose. They are the concentration in the product name.

The dose window shows Soliqua units. Each displayed unit carries 1 unit of insulin glargine and about 0.33 mcg of lixisenatide. The label table starts at 15 displayed units and goes up to 60 displayed units, with 60 units equal to 60 units insulin glargine and 20 mcg lixisenatide.

That fixed ratio is the whole trick:

This is label math, not a dosing plan. The full label has starting-dose and titration instructions because clinicians need them.

3. How Are Soliqua, Lantus, and Adlyxin Related?

Sanofi’s 2016 approval announcement described Soliqua 100/33 as a once-daily fixed-ratio combination of insulin glargine, associated with Lantus, and lixisenatide, associated with Adlyxin. Connected ingredients, separate labels.

The relationship is ingredient-based. Lantus is insulin glargine branding. Adlyxin is lixisenatide branding. Soliqua puts insulin glargine and lixisenatide together in one fixed-ratio product.

That can get messy in records. “Glargine” can mean Lantus, Basaglar, Toujeo, or plain insulin glargine. “Lixisenatide” can mean Adlyxin. Soliqua overlaps with those ingredient names, but it does not become the same product as either brand.

Soliqua combines the insulin glargine ingredient associated with Lantus and the lixisenatide ingredient associated with Adlyxin, but Soliqua is its own label.

4. Who Is the Soliqua Label About?

CDC says type 2 diabetes accounts for about 90% to 95% of diagnosed diabetes cases in the United States. Soliqua’s current U.S. label sits in adult type 2 diabetes, and the label says it is not recommended for diabetic ketoacidosis.

The patient labeling also says Soliqua has not been studied in people who take short-acting, or prandial, insulin. It says use with lixisenatide or another GLP-1 receptor agonist is not recommended. Children are another boundary: the label says it is not known whether Soliqua is safe and effective in children.

This is where casual shorthand breaks down. If a medication list says only “GLP-1,” Soliqua’s insulin component disappears. If it says only “glargine,” lixisenatide disappears. Both omissions matter.

5. Why the First-Meal Wording Gets Attention

DailyMed says Soliqua is injected once a day within the hour before the first meal of the day. That timing language is part of the label and differs from Xultophy’s same-time-each-day wording.

The point is not to tell someone when to inject. Route and timing are product-specific facts. Soliqua, Xultophy, Lantus, Adlyxin, Victoza, Ozempic, and Mounjaro are not interchangeable labels with one shared instruction set.

The first-meal wording also explains why Soliqua can be confusing in a tracker. A person may log a “daily insulin” time, a “GLP-1” time, or a breakfast-adjacent dose, but those are not the same record. A Soliqua entry needs brand, active ingredients, displayed units, source date, and any clinician-provided instructions kept separate.

A plain recordkeeping format looks like this:

That sort of note looks dull on purpose. Dull records are harder to misread.

6. Soliqua vs Xultophy

Xultophy 100/3.6 is the closest comparison because it is also a fixed-ratio insulin and GLP-1 receptor agonist combination. The current DailyMed Xultophy label lists insulin degludec and liraglutide. Soliqua lists insulin glargine and lixisenatide.

Same product idea. Different ingredients.

That table is not a scorecard. It does not compare A1C outcomes for a defined study population, adverse-reaction rates, timing, insurance coverage, pharmacy access, or whether either product fits someone’s care plan. It highlights one specific detail: Soliqua and Xultophy are related by product type, but they are different combinations.

7. Safety Language From the Soliqua Label

The current Soliqua label lists warnings for anaphylaxis and serious hypersensitivity reactions, acute pancreatitis, pen sharing, hyperglycemia or hypoglycemia with insulin-regimen changes, overdose due to medication errors, hypoglycemia, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, immunogenicity, hypokalemia, fluid retention with certain PPAR-gamma agonists, and pulmonary aspiration during general anesthesia or deep sedation.

Quite a lot. That is why product-label facts cannot answer “should I take it?” questions.

Medication-error wording is especially relevant because Soliqua contains two active ingredients. The label says more than 60 units daily can overdose the lixisenatide component, and it tells patients not to use Soliqua with other GLP-1 receptor agonists. It also tells patients to check the pen label before injection and not to share pens.

Those facts belong with the source label. They do not become personal medical guidance.

8. What Facts Should You Track?

The most useful Soliqua facts are brand, active ingredients, concentration, displayed units, route, label context, label maximum, and source date. Those fields keep the insulin part and the GLP-1 part visible at the same time.

For a neutral record, this is enough:

For broader category background, see What Is a GLP-1?. For the other fixed-ratio combination, see What Is Xultophy?. For recordkeeping rather than drug selection, GLP-1 Dose Tracker covers how to keep notes without turning them into medical advice.

9. What Is Soliqua FAQ

• What is Soliqua in simple terms?

  Soliqua 100/33 is a prescription injection that combines insulin glargine, a long-acting insulin analog, with lixisenatide, a GLP-1 receptor agonist. Current U.S. labeling places it in adult type 2 diabetes glycemic-control context.

• Is Soliqua a GLP-1?

  Soliqua contains lixisenatide, which is a GLP-1 receptor agonist. It also contains insulin glargine. That insulin component means Soliqua should be read as a fixed-ratio combination product, not as a plain GLP-1 brand.

• What does Soliqua 100/33 mean?

  The numbers describe the concentration in the pen: 100 units/mL insulin glargine and 33 mcg/mL lixisenatide. Each displayed unit contains 1 unit of insulin glargine and about 0.33 mcg of lixisenatide.

• Is Soliqua the same as Lantus or Adlyxin?

  No. Lantus is insulin glargine branding. Adlyxin is lixisenatide branding. Soliqua combines insulin glargine and lixisenatide in one fixed-ratio SoloStar pen, so the brand context is different.

• How is Soliqua different from Xultophy?

  Both are fixed-ratio insulin and GLP-1 receptor agonist combinations for adults with type 2 diabetes, but they use different ingredients. Soliqua contains insulin glargine and lixisenatide. Xultophy contains insulin degludec and liraglutide.

10. Sources